title: A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study.
abstract: BACKGROUND
  The implementation of a public HPV vaccination program in several developing countries, especially in Latin America, is a great challenge for health care specialists.
  
  
  OBJECTIVE
  To evaluate the uptake and the three-dose completion rates of a school-based HPV vaccination program in Barretos (Brazil).
  
  
  METHODS
  THE STUDY INCLUDED GIRLS WHO WERE ENROLLED IN PUBLIC AND PRIVATE SCHOOLS AND WHO REGULARLY ATTENDED THE SIXTH AND SEVENTH GRADES OF ELEMENTARY SCHOOL (MEAN AGE: 11.9 years). A meeting with the parents or guardians occurred approximately one week before the vaccination in order to explain the project and clarify the doubts. The quadrivalent vaccine was administered using the same schedule as in the product package (0-2-6 months). The school visits for regular vaccination occurred on previously scheduled dates. The vaccine was also made available at Barretos Cancer Hospital for the girls who could not be vaccinated on the day when the team visited the school.
  
  
  RESULTS
  Among the potential candidates for vaccination (n = 1,574), the parents or guardians of 1,513 girls (96.1%) responded to the invitation to participate in the study. A total of 1,389 parents or guardians agreed to participate in the program (acceptance rate = 91.8%). The main reason for refusing to participate in the vaccination program was fear of adverse events. The vaccine uptake rates for the first, second, and third doses were 87.5%, 86.3% and 85.0%, respectively. The three-dose completion rate was 97.2%.
  
  
  CONCLUSIONS
  This demonstrative study achieved high rates of vaccination uptake and completion of three vaccine doses in children 10-16 years old from Brazil. The feasibility and success of an HPV vaccination program for adolescents in a developing country may depend on the integration between the public health and schooling systems.
authors: Research and Teaching Institute - Barretos Cancer Hospital (IEP - HCB), Barretos, Brazil. mdfregnani@terra.com.br
authors: José Humberto Tavares Guerreiro
authors: JH
authors: Fregnani
authors: André Lopes
authors: AL
authors: Carvalho
authors: José
authors: J
authors: Eluf-Neto
authors: Karina de Cássia Braga
authors: Kde C
authors: Ribeiro
authors: Larissa de Melo
authors: Lde M
authors: Kuil
authors: Tauana Arcadepani
authors: TA
authors: da Silva
authors: Silvia Lapola
authors: SL
authors: Rodrigues
authors: Edmundo Carvalho
authors: EC
authors: Mauad
authors: Adhemar
authors: A
authors: Longatto-Filho
authors: Luisa Lina
authors: LL
authors: Villa
mesh_terms: D000293:Adolescent; D001938:Brazil; D002648:Child; D003906:Developing Countries; D005260:Female; D006801:Humans; D017589:Immunization Programs; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D010342:Patient Acceptance of Health Care; D012574:Schools; D012959:Socioeconomic Factors
chemical_list: D053918:Papillomavirus Vaccines
references: Vaccine. 2007 Aug 14;25(33):6257-70
references: 17606315
references: Lancet. 2009 Jul 25;374(9686):301-14
references: 19586656
references: N Engl J Med. 2007 May 10;356(19):1928-43
references: 17494926
references: Lancet Oncol. 2012 Jan;13(1):89-99
references: 22075171
references: Cancer Lett. 2011 Jun 28;305(2):106-12
references: 21190794
references: Vaccine. 2011 Dec 6;29(52):9663-7
references: 22015392
references: Bull World Health Organ. 2011 Nov 1;89(11):821-830B
references: 22084528
references: J Adolesc Health. 2010 Sep;47(3):237-41
references: 20708561
references: MMWR Morb Mortal Wkly Rep. 2012 Aug 31;61(34):671-7
references: 22932301
references: MMWR Morb Mortal Wkly Rep. 2010 Aug 20;59(32):1018-23
references: 20724968
references: Euro Surveill. 2011 May 26;16(21):
references: 21632017
references: Prev Med. 2011 Oct;53 Suppl 1:S29-35
references: 21962468
references: Lancet Oncol. 2005 May;6(5):271-8
references: 15863374
references: N Engl J Med. 2007 May 10;356(19):1915-27
references: 17494925
references: Vaccine. 2010 Feb 25;28(9):2070-5
references: 20045095
references: Aust N Z J Public Health. 2009 Aug;33(4):365-70
references: 19689598
references: J Infect Dis. 2012 Sep 1;206(5):678-86
references: 22711908
references: Vaccine. 2006 Aug 31;24 Suppl 3:S3/52-61
references: 16950018
references: Vaccine. 2011 Apr 27;29(19):3610-6
references: 21382486
references: MMWR Morb Mortal Wkly Rep. 2011 Oct 14;60(40):1382-4
references: 21993342
references: Vaccine. 2011 Jun 10;29(26):4405-8
references: 21501645
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28
references: 17237032
references: Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25
references: 16949997
references: Pediatrics. 2011 Dec;128(6):1078-86
references: 22084326
references: Sex Transm Infect. 2009 Dec;85(7):499-502
references: 19837728
references: Wkly Epidemiol Rec. 2009 Apr 10;84(15):118-31
references: 19360985
references: Vaccine. 2012 Mar 23;30(14):2467-74
references: 22266289
references: Br J Cancer. 2006 Dec 4;95(11):1459-66
references: 17117182
references: Asian Pac J Cancer Prev. 2010;11(3):615-7
references: 21039025
references: Euro Surveill. 2009 Nov 19;14(46):
references: 19941796
references: Lancet. 2011 Jun 18;377(9783):2085-92
references: 21684381
references: BMC Public Health. 2012 May 23;12:370
references: 22621342
references: Vaccine. 2012 Jul 6;30(32):4866-71
references: 22652405